GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Cash Conversion Cycle

Shanghai Haohai Biological Technology Co (HKSE:06826) Cash Conversion Cycle : 259.91 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Shanghai Haohai Biological Technology Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 46.53.
Shanghai Haohai Biological Technology Co's Days Inventory for the three months ended in Mar. 2024 was 243.97.
Shanghai Haohai Biological Technology Co's Days Payable for the three months ended in Mar. 2024 was 30.59.
Therefore, Shanghai Haohai Biological Technology Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 259.91.


Shanghai Haohai Biological Technology Co Cash Conversion Cycle Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Cash Conversion Cycle Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 270.54 323.68 268.95 282.11 262.42

Shanghai Haohai Biological Technology Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 276.98 257.86 289.32 243.77 259.91

Competitive Comparison of Shanghai Haohai Biological Technology Co's Cash Conversion Cycle

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Cash Conversion Cycle falls into.



Shanghai Haohai Biological Technology Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Shanghai Haohai Biological Technology Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=49.69+238.6-25.87
=262.42

Shanghai Haohai Biological Technology Co's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=46.53+243.97-30.59
=259.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co  (HKSE:06826) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Shanghai Haohai Biological Technology Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Dalton Investments Llc 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc 2102 Investment manager
Kabouter Management Llc 2102 Investment manager
Royal Bank Of Canada 2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc 2102 Investment manager
Prudence Investment Management (hong Kong) Limited 2102 Investment manager

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines